March 22, 2013 at 09:59 AM EDT
UPDATE: Canaccord Genuity Initiates Insmed at Buy on New Treatment for Lung Infections
In a report published by Canaccord Genuity, analyst Ritu Baral initiated coverage on Insmed (NASDAQ: INSM ) with a Buy rating and a $12 price target. Canaccord Genuity reported that, “Initiating coverage with BUY rating, $12 target on Arikace potential in two orphan indications: cystic fibrosis (CF) P. aeruginosa and
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here